{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T08:34:59Z","timestamp":1790670899384,"version":"4.1.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Atheroscler Rep"],"published-print":{"date-parts":[[2020,5]]},"DOI":"10.1007\/s11883-020-00836-w","type":"journal-article","created":{"date-parts":[[2020,5,26]],"date-time":"2020-05-26T06:03:32Z","timestamp":1590473012000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":40,"title":["Efficacy and Safety of Volanesorsen (ISIS 304801): the Evidence from Phase 2 and 3 Clinical Trials"],"prefix":"10.1007","volume":"22","author":[{"given":"Federica","family":"Fogacci","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe Danilo","family":"Norata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter P.","family":"Toth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcello","family":"Arca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4367-3884","authenticated-orcid":false,"given":"Arrigo F. G.","family":"Cicero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,5,26]]},"reference":[{"issue":"2","key":"836_CR1","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.ccl.2017.12.008","volume":"36","author":"M Kockx","year":"2018","unstructured":"Kockx M, Kritharides L. Triglyceride-rich lipoproteins. Cardiol Clin. 2018;36(2):265\u201375. https:\/\/doi.org\/10.1016\/j.ccl.2017.12.008.","journal-title":"Cardiol Clin"},{"issue":"8","key":"836_CR2","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1016\/S2213-8587(13)70191-8","volume":"2","author":"RA Hegele","year":"2014","unstructured":"Hegele RA, Ginsberg HN, Chapman MJ, Nordestgaard BG, Kuivenhoven JA, Averna M, et al. European atherosclerosis society consensus panel. The polygenic nature of hypertriglyceridaemia: implications for definition, diagnosis, and management. Lancet Diabetes Endocrinol. 2014;2(8):655\u201366. https:\/\/doi.org\/10.1016\/S2213-8587(13)70191-8.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"2","key":"836_CR3","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1194\/jlr.R009720","volume":"52","author":"CT Johansen","year":"2011","unstructured":"Johansen CT, Kathiresan S, Hegele RA. Genetic determinants of plasma triglycerides. J Lipid Res. 2011;52(2):189\u2013206. https:\/\/doi.org\/10.1194\/jlr.R009720.","journal-title":"J Lipid Res"},{"issue":"6","key":"836_CR4","doi-asserted-by":"publisher","first-page":"1482","DOI":"10.1016\/j.jacl.2018.07.013","volume":"12","author":"MJ Ariza","year":"2018","unstructured":"Ariza MJ, Rioja J, Ibarretxe D, Camacho A, D\u00edaz-D\u00edaz JL, Mangas A, et al. Spanish Dyslipidemia Registry. Molecular basis of the familial chylomicronemia syndrome in patients from the National Dyslipidemia Registry of the Spanish Atherosclerosis Society. J Clin Lipidol. 2018;12(6):1482\u20131492.e3. https:\/\/doi.org\/10.1016\/j.jacl.2018.07.013.","journal-title":"J Clin Lipidol"},{"issue":"3","key":"836_CR5","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1080\/03007995.2018.1533459","volume":"35","author":"C Vatier","year":"2019","unstructured":"Vatier C, Vantyghem MC, Storey C, J\u00e9ru I, Christin-Maitre S, F\u00e8ve B, et al. Monogenic forms of lipodystrophic syndromes: diagnosis, detection, and practical management considerations from clinical cases. Curr Med Res Opin. 2019;35(3):543\u201352. https:\/\/doi.org\/10.1080\/03007995.2018.1533459.","journal-title":"Curr Med Res Opin"},{"issue":"8","key":"836_CR6","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1210\/js.2019-00129","volume":"3","author":"MI Esparza","year":"2019","unstructured":"Esparza MI, Li X, Adams-Huet B, Vasandani C, Vora A, Das SR, et al. Very severe hypertriglyceridemia in a large US County health care system: associated conditions and management. J Endocr Soc. 2019;3(8):1595\u2013607. https:\/\/doi.org\/10.1210\/js.2019-00129Update estimation of severe hypertrglyceridemia in a large population cohort.","journal-title":"J Endocr Soc"},{"issue":"10","key":"836_CR7","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1080\/14656566.2019.1604687","volume":"20","author":"AFG Cicero","year":"2019","unstructured":"Cicero AFG, Landolfo M, Ventura F, Borghi C. Current pharmacotherapeutic options for primary dyslipidemia in adults. Expert Opin Pharmacother. 2019;20(10):1277\u201388. https:\/\/doi.org\/10.1080\/14656566.2019.1604687.","journal-title":"Expert Opin Pharmacother"},{"key":"836_CR8","doi-asserted-by":"publisher","unstructured":"Shukla V, Seoane-Vazquez E, Fawaz S, Brown L, Rodriguez-Monguio R. The landscape of cellular and gene therapy products: authorization, discontinuations, and cost. Hum Gene Ther Clin Dev. 2019. https:\/\/doi.org\/10.1089\/humc.2018.201.","DOI":"10.1089\/humc.2018.201"},{"key":"836_CR9","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1016\/j.atherosclerosis.2017.12.017","volume":"269","author":"F Fogacci","year":"2018","unstructured":"Fogacci F, Cicero AF. Gene targeting for chylomicronemia syndrome: the brave new world. Atherosclerosis. 2018;269:254\u20135. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2017.12.017.","journal-title":"Atherosclerosis."},{"issue":"4","key":"836_CR10","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.tips.2013.01.010","volume":"34","author":"GD Norata","year":"2013","unstructured":"Norata GD, Tibolla G, Catapano AL. Gene silencing approaches for the management of dyslipidaemia. Trends Pharmacol Sci. 2013;34(4):198\u2013205. https:\/\/doi.org\/10.1016\/j.tips.2013.01.010.","journal-title":"Trends Pharmacol Sci"},{"issue":"10","key":"836_CR11","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1016\/j.tips.2015.07.001","volume":"36","author":"GD Norata","year":"2015","unstructured":"Norata GD, Tsimikas S, Pirillo A, Catapano AL. Apolipoprotein C-III: From pathophysiology to pharmacology. Trends Pharmacol Sci. 2015;36(10):675\u201387. https:\/\/doi.org\/10.1016\/j.tips.2015.07.001.","journal-title":"Trends Pharmacol Sci"},{"issue":"12","key":"836_CR12","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1007\/s40265-019-01168-z","volume":"79","author":"J Paik","year":"2019","unstructured":"Paik J, Duggan S. Volanesorsen: First Global Approval. Drugs. 2019;79(12):1349\u201354. https:\/\/doi.org\/10.1007\/s40265-019-01168-z.","journal-title":"Drugs."},{"issue":"7","key":"836_CR13","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1080\/14740338.2019.1620730","volume":"18","author":"L Strilchuk","year":"2019","unstructured":"Strilchuk L, Fogacci F, Cicero AF. Safety and tolerability of injectable lipid-lowering drugs: an update of clinical data. Expert Opin Drug Saf. 2019;18(7):611\u201321. https:\/\/doi.org\/10.1080\/14740338.2019.1620730.","journal-title":"Expert Opin Drug Saf"},{"key":"836_CR14","doi-asserted-by":"publisher","first-page":"b2535","DOI":"10.1136\/bmj.b2535","volume":"339","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009;339:b2535. https:\/\/doi.org\/10.1136\/bmj.b2535.","journal-title":"BMJ"},{"key":"836_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.phrs.2019.02.028","volume":"143","author":"F Fogacci","year":"2019","unstructured":"Fogacci F, Banach M, Mikhailidis DP, Bruckert E, Toth PP, Watts GF, et al. Safety of red yeast rice supplementation: a systematic review and meta-analysis of randomized controlled trials. Pharmacol Res. 2019;143:1\u201316. S1043\u20136618(19)30317\u20132. https:\/\/doi.org\/10.1016\/j.phrs.2019.02.028.","journal-title":"Pharmacol Res"},{"key":"836_CR16","doi-asserted-by":"publisher","unstructured":"Fogacci S, Fogacci F, Banach M, Michos ED, Hernandez AV, Lip GYH, et al. Vitamin D supplementation and incident preeclampsia: A systematic review and meta-analysis of randomized clinical trials. Clin Nutr. 2019. https:\/\/doi.org\/10.1016\/j.clnu.2019.08.015.","DOI":"10.1016\/j.clnu.2019.08.015"},{"key":"836_CR17","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions. Version 5.0. 2. 2009","author":"J Higgins","year":"2010","unstructured":"Higgins J, Green S. Cochrane Handbook for Systematic Reviews of Interventions. Version 5.0. 2. 2009. Chichester: John Wiley and Sons Ltd. Ref Type: Report; 2010."},{"issue":"4","key":"836_CR18","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1002\/ptr.6282","volume":"33","author":"F Fogacci","year":"2019","unstructured":"Fogacci F, Grassi D, Rizzo M, Cicero AFG. Metabolic effect of berberine-silymarin association: a meta-analysis of randomized, double-blind, placebo-controlled clinical trials. Phytother Res. 2019;33(4):862\u201370. https:\/\/doi.org\/10.1002\/ptr.6282.","journal-title":"Phytother Res"},{"issue":"7650","key":"836_CR19","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","volume":"336","author":"GH Guyatt","year":"2008","unstructured":"Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336(7650):924\u20136. https:\/\/doi.org\/10.1136\/bmj.39489.470347.AD.","journal-title":"BMJ."},{"key":"836_CR20","first-page":"104","volume-title":"Comprehensive meta-analysis version 3","author":"M Borenstein","year":"2005","unstructured":"Borenstein M, Hedges L, Higgins J, Rothstein H. Comprehensive meta-analysis version 3. Englewood: Biostat; 2005. p. 104."},{"issue":"7","key":"836_CR21","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1016\/0895-4356(92)90054-Q","volume":"45","author":"D Follmann","year":"1992","unstructured":"Follmann D, Elliott P, Suh I, Cutler J. Variance imputation for overviews of clinical trials with continuous response. J Clin Epidemiol. 1992;45(7):769\u201373.","journal-title":"J Clin Epidemiol"},{"key":"836_CR22","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1186\/1471-2288-14-135","volume":"14","author":"X Wan","year":"2014","unstructured":"Wan X, Wang W, Liu J, Tong T. Estimating the sample mean and standard deviation from the sample size, median, range and\/or interquartile range. BMC Med Res Methodol. 2014;14:135. https:\/\/doi.org\/10.1186\/1471-2288-14-135.","journal-title":"BMC Med Res Methodol"},{"key":"836_CR23","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1111\/1469-0691.12494","volume":"20","author":"WG Melsen","year":"2014","unstructured":"Melsen WG, Bootsma MC, Rovers MM, Bonten MJ. The effects of clinical and statistical heterogeneity on the predictive values of results from meta-analyses. Clin Microbiol Infect. 2014;20:123\u20139. https:\/\/doi.org\/10.1111\/1469-0691.12494.","journal-title":"Clin Microbiol Infect"},{"issue":"7","key":"836_CR24","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1007\/s40265-019-01114-z","volume":"79","author":"F Fogacci","year":"2019","unstructured":"Fogacci F, Ferri N, Toth PP, Ruscica M, Corsini A, Cicero AFG. Efficacy and safety of Mipomersen: a systematic review and meta-analysis of randomized clinical trials. Drugs. 2019;79(7):751\u201366. https:\/\/doi.org\/10.1007\/s40265-019-01114-z.","journal-title":"Drugs."},{"issue":"6","key":"836_CR25","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/0021-9681(56)90049-2","volume":"4","author":"W Haenszel","year":"1956","unstructured":"Haenszel W, Hon NB. Statistical approaches to the study of cancer with particular reference to case registers. J Chronic Dis. 1956;4(6):589\u201399.","journal-title":"J Chronic Dis"},{"issue":"39","key":"836_CR26","doi-asserted-by":"publisher","first-page":"4490","DOI":"10.2174\/0929867323666161007155310","volume":"23","author":"A Sahebkar","year":"2016","unstructured":"Sahebkar A, Pirro M, Reiner \u017d, Cicero AF, Simental-Mendia L, Simental-Mendia LE. A systematic review and meta-analysis of controlled trials on the effects of statin and fibrate therapies on plasma Homocysteine levels. Curr Med Chem. 2016;23(39):4490\u2013503.","journal-title":"Curr Med Chem"},{"key":"836_CR27","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1111\/j.0006-341X.2000.00455.x","volume":"56","author":"S Duval","year":"2000","unstructured":"Duval S, Tweedie R. Trim and fill: a simple funnel-plot\u2013based method of testing and adjusting for publication bias in meta-analysis. Biometrics. 2000;56:455\u201363.","journal-title":"Biometrics."},{"issue":"6","key":"836_CR28","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1056\/NEJMoa1715944","volume":"381","author":"JL Witztum","year":"2019","unstructured":"Witztum JL, Gaudet D, Freedman SD, Alexander VJ, Digenio A, Williams KR, et al. Volanesorsen and triglyceride levels in familial Chylomicronemia syndrome. N Engl J Med. 2019;381(6):531\u201342. https:\/\/doi.org\/10.1056\/NEJMoa1715944Main trial demonstrating the volanesorsen efficacy and safety in FCS patients.","journal-title":"N Engl J Med"},{"issue":"8","key":"836_CR29","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.2337\/dc16-0126","volume":"39","author":"A Digenio","year":"2016","unstructured":"Digenio A, Dunbar RL, Alexander VJ, Hompesch M, Morrow L, Lee RG, et al. Antisense-mediated lowering of plasma Apolipoprotein C-III by Volanesorsen improves dyslipidemia and insulin sensitivity in type 2 diabetes. Diabetes Care. 2016;39(8):1408\u201315. https:\/\/doi.org\/10.2337\/dc16-0126.","journal-title":"Diabetes Care"},{"issue":"5","key":"836_CR30","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1056\/NEJMoa1400283","volume":"373","author":"D Gaudet","year":"2015","unstructured":"Gaudet D, Alexander VJ, Baker BF, Brisson D, Tremblay K, Singleton W, et al. Antisense inhibition of Apolipoprotein C-III in patients with hypertriglyceridemia. N Engl J Med. 2015;373(5):438\u201347. https:\/\/doi.org\/10.1056\/NEJMoa1400283.","journal-title":"N Engl J Med"},{"key":"836_CR31","doi-asserted-by":"publisher","unstructured":"Chyzhyk V, Brown AS. Familial chylomicronemia syndrome: A rare but devastating autosomal recessive disorder characterized by refractory hypertriglyceridemia and recurrent pancreatitis. Trends Cardiovasc Med. 2019. https:\/\/doi.org\/10.1016\/j.tcm.2019.03.001.","DOI":"10.1016\/j.tcm.2019.03.001"},{"issue":"3","key":"836_CR32","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1016\/j.jacc.2018.04.061","volume":"72","author":"OP Ganda","year":"2018","unstructured":"Ganda OP, Bhatt DL, Mason RP, Miller M, Boden WE. Unmet need for adjunctive dyslipidemia therapy in hypertriglyceridemia management. J Am Coll Cardiol. 2018;72(3):330\u201343. https:\/\/doi.org\/10.1016\/j.jacc.2018.04.061.","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"836_CR33","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1056\/NEJMoa1308027","volume":"371","author":"AB J\u00f8rgensen","year":"2014","unstructured":"J\u00f8rgensen AB, Frikke-Schmidt R, Nordestgaard BG, Tybj\u00e6rg-Hansen A. Loss-of-function mutations in APOC3 and risk of ischemic vascular disease. N Engl J Med. 2014;371(1):32\u201341. https:\/\/doi.org\/10.1056\/NEJMoa1308027.","journal-title":"N Engl J Med"},{"issue":"1","key":"836_CR34","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1056\/NEJMoa1307095","volume":"371","author":"J Crosby","year":"2014","unstructured":"TG and HDL Working Group of the Exome Sequencing Project, National Heart, Lung, and Blood Institute, Crosby J, Peloso GM, Auer PL, Crosslin DR, Stitziel NO, et al. Loss-of-function mutations in APOC3, triglycerides, and coronary disease. N Engl J Med. 2014;371(1):22\u201331. https:\/\/doi.org\/10.1056\/NEJMoa1307095.","journal-title":"N Engl J Med"},{"issue":"6","key":"836_CR35","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1097\/MOL.0000000000000130","volume":"25","author":"SJ Bernelot Moens","year":"2014","unstructured":"Bernelot Moens SJ, van Capelleveen JC, Stroes ES. Inhibition of ApoCIII: the next PCSK9? Curr Opin Lipidol. 2014;25(6):418\u201322. https:\/\/doi.org\/10.1097\/MOL.0000000000000130.","journal-title":"Curr Opin Lipidol"},{"issue":"10","key":"836_CR36","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1042\/CS20070308","volume":"114","author":"EM Ooi","year":"2008","unstructured":"Ooi EM, Barrett PH, Chan DC, Watts GF. Apolipoprotein C-III: understanding an emerging cardiovascular risk factor. Clin Sci (Lond). 2008;114(10):611\u201324. https:\/\/doi.org\/10.1042\/CS20070308.","journal-title":"Clin Sci (Lond)"},{"issue":"4","key":"836_CR37","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1016\/j.jacl.2015.05.002","volume":"9","author":"MC Wyler von Ballmoos","year":"2015","unstructured":"Wyler von Ballmoos MC, Haring B, Sacks FM. The risk of cardiovascular events with increased apolipoprotein CIII: A systematic review and meta-analysis. J Clin Lipidol. 2015;9(4):498\u2013510. https:\/\/doi.org\/10.1016\/j.jacl.2015.05.002An interesting meta-analysis linking the apoCIII plasma level and cardiovascular risk.","journal-title":"J Clin Lipidol"},{"issue":"7","key":"836_CR38","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1080\/14779072.2018.1487290","volume":"16","author":"M Arca","year":"2018","unstructured":"Arca M, Hsieh A, Soran H, Rosenblit P, O'Dea L, Stevenson M. The effect of volanesorsen treatment on the burden associated with familial chylomicronemia syndrome: the results of the ReFOCUS study. Expert Rev Cardiovasc Ther. 2018;16(7):537\u201346. https:\/\/doi.org\/10.1080\/14779072.2018.1487290.","journal-title":"Expert Rev Cardiovasc Ther"},{"issue":"6","key":"836_CR39","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1161\/CIRCULATIONAHA.118.039107","volume":"140","author":"Z Ahmad","year":"2019","unstructured":"Ahmad Z, Banerjee P, Hamon S, Chan KC, Bouzelmat A, Sasiela WJ, et al. Inhibition of Angiopoietin-like protein 3 with a monoclonal antibody reduces triglycerides in hypertriglyceridemia. Circulation. 2019;140(6):470\u201386. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.118.039107.","journal-title":"Circulation."},{"issue":"7","key":"836_CR40","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1194\/jlr.M054882","volume":"56","author":"Y Wang","year":"2015","unstructured":"Wang Y, Gusarova V, Banfi S, Gromada J, Cohen JC, Hobbs HH. Inactivation of ANGPTL3 reduces hepatic VLDL-triglyceride secretion. J Lipid Res. 2015;56(7):1296\u2013307. https:\/\/doi.org\/10.1194\/jlr.M054882.","journal-title":"J Lipid Res"},{"key":"836_CR41","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s12944-015-0006-5","volume":"14","author":"CD Meyers","year":"2015","unstructured":"Meyers CD, Tremblay K, Amer A, Chen J, Jiang L, Gaudet D. Effect of the DGAT1 inhibitor pradigastat on triglyceride and apoB48 levels in patients with familial chylomicronemia syndrome. Lipids Health Dis. 2015;14:8. https:\/\/doi.org\/10.1186\/s12944-015-0006-5.","journal-title":"Lipids Health Dis"},{"key":"836_CR42","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.atherosclerosissup.2016.10.002","volume":"23","author":"E Stroes","year":"2017","unstructured":"Stroes E, Moulin P, Parhofer KG, Rebours V, L\u00f6hr JM, Averna M. Diagnostic algorithm for familial chylomicronemia syndrome. Atheroscler Suppl. 2017;23:1\u20137. https:\/\/doi.org\/10.1016\/j.atherosclerosissup.2016.10.002A practical approach to detect FCS in clinical practice.","journal-title":"Atheroscler Suppl"}],"container-title":["Current Atherosclerosis Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11883-020-00836-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11883-020-00836-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11883-020-00836-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,25]],"date-time":"2021-05-25T23:47:26Z","timestamp":1621986446000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11883-020-00836-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5]]},"references-count":42,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,5]]}},"alternative-id":["836"],"URL":"https:\/\/doi.org\/10.1007\/s11883-020-00836-w","relation":{},"ISSN":["1523-3804","1534-6242"],"issn-type":[{"value":"1523-3804","type":"print"},{"value":"1534-6242","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5]]},"assertion":[{"value":"26 May 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"<i>Federica Fogacci<\/i> has served as a consultant to Mylan; <i>Danilo Giuseppe Norata<\/i> reports grants from Pfizer, Amgen, Alnylam, and Sanofi; <i>Peter P. Toth<\/i> reports personal fees from Amgen, Amarin, Kowa, Novo Nordisk, Resverlogix, Regeneron, and Sanofi; <i>Marcello Arca<\/i> reports grants from Akcea\/Ionis; <i>Arrigo F.G. Cicero<\/i> has given talks, furnished scientific consultancies, and\/or participated in trials sponsored by Amgen, Angelini, Menarini, and Mylan.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}],"article-number":"18"}}